Trial Profile
An Exploratory, Open-Label Study of the Safety and Efficacy of High Dose or High Dosing Frequency Alglucosidase Alfa Treatment in Patients With Pompe Disease Who Do Not Have an Optimal Response to the Standard Dose Regimen
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Feb 2016
Price :
$35
*
At a glance
- Drugs Alglucosidase alfa (Primary)
- Indications Glycogen storage disease type II
- Focus Therapeutic Use
- Sponsors Genzyme Corporation
- 01 Feb 2016 New trial record